Pentaglobin in steroid-resistant severe acute respiratory syndrome

International Journal of Tuberculosis and Lung Disease

Volumn 8, Issue 10, 2004, Pages 1173-1179

  Ho, J C ^a   Wu, A Y ^a   Lam, B ^a   Ooi, G C ^a   Khong, P L ^a   Ho, P L ^a   Chan Yeung, M ^a   Zhong, N S ^b   Ko, C ^a   Lam, W K ^a   Tsang, Kenneth W ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Corticosteroid; Immunoglobulin; Pentaglobin; Severe acute respiratory syndrome; Treatment

Indexed keywords

CEFEPIME; CLARITHROMYCIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; METHYLPREDNISOLONE; OXYGEN; PREDNISOLONE; RIBAVIRIN; STEROID;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; CAUSE OF DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; OXYGEN THERAPY; PATIENT SELECTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; SIDE EFFECT; STEROID THERAPY; THORAX RADIOGRAPHY; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; DRUG RESISTANCE; FEMALE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RIBAVIRIN; SEVERE ACUTE RESPIRATORY SYNDROME; TREATMENT OUTCOME;

EID: 5644259643     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Rota P A, Oberste M S, Monroe S S, et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 2003; 300: 1394-1399.
2. World Health Organization. Cumulative number of reported probable cases. Geneva, Switzerland, WHO, 2003. www.who.int/csr/sars/country/2003_06_18/en/ Accessed 18 June 2003.
3. Wenzel R P, Edmond M B. Managing SARS amidst uncertainty. N Engl J Med 2003; 348: 1947-1948.
4. Cyranoski D. Critics slam treatment for SARS as ineffective and perhaps dangerous. Nature 2003; 423: 4.
5. Booth C M, Matukas L M, Tomlinson G A, et al. Clinical features and short-term outcomes of 144 patients with SARS in the Greater Toronto Area. JAMA 2003; 289: 2801-2809.
6. Tsang K W, Ho P L, Ooi G C, et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003; 348: 1977-1985.
7. Tsang K W, Lam W K. Management of severe acute respiratory syndrome - the University of Hong Kong experience. Am J Respir Crit Care Med 2003; 168: 417-424.
8. Lee N, Hui D, Wu A, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003; 348: 1986-1994.
9. Nicholls J M,Poon L L, Lee K C, et al. Lung pathology of fatal severe acute respiratory syndrome. Lancet 2003; 361: 1773-1778.
10. Kaveri S V, Dietrich G, Hurez V, Kazatchkine M D. Intravenous immunoglobulins (IVIg) in the treatment of autoimmune disease. Clin Exp Immunol 1991; 86: 192-198.
11. Dwyer J M. Manipulating the immune system with immune globulin. N Engl J Med 1992; 326: 107-116.
12. Andersson U, Björk L, Skansen-Saphir U, Andersson J. Pooled human IgG modulates cytokine production in lymphocytes and monocytes. Immunol Rev 1994; 139: 21-42.
13. Nachbaur D, Herold M, Gächter A, Niederwieser D. Modulation of alloimmune response in vitro by an IgM-enriched immunoglobulin preparation (Pentaglobin). Immunology 1998; 94: 279-283.
14. World Health Organization. Severe acute respiratory syndrome: case definitions for surveillance of SARS. Geneva, Switzerland, WHO, 2003. www.who.int/csr/sars/casedefinition/en/ Accessed May 28, 2003.
15. Centers for Disease Control and Prevention. Severe Acute Respiratory Syndrome (SARS). Diagnosis/Evaluation. May 20, 2003. Atlanta, GA: CDC, 2003. www.cdc.gov/ncidod/sars/diagnosis.htm
16. Peiris J S, Lai S T, Poon L L, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003; 361: 1319-1325.
17. Peiris J S, Chu C M, Cheng V C, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 2003; 361: 1767-1772.
18. So L K, Lau A C, Yam L Y, et al. Development of a standard treatment protocol for severe acute respiratory syndrome. Lancet 2003; 361: 1615-1617.
19. Ooi G C, Khong P L, Lam B, et al. Severe acute respiratory syndrome: relationship between radiologic and clinical parameters. Radiology 2003; 229: 492-499.
20. SARS Expert Committee. SARS in Hong Kong: from experience to action. Hong Kong SAR, China: www.sars-expertcom.gov.hk/english/reports/summary/files/ e_sumprt_fulltext.pdf Accessed 2 August 2004.
21. Jones B M, Ma E S, Peiris J S, et al. Prolonged disturbances of in vitro cytokine production in patients with severe acute respiratory syndrome (SARS) treated with ribavirin and steroids. Clin Exp Immunol 2004; 135: 467-473.
22. To K F, Chan P K, Chan K F, et al. Pathology of fatal human infection associated with avian influenza A H5N1 virus. J Med Virol 2001; 63: 242-246.
23. Cheung C Y, Poon L L, Lau A S, et al. Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? Lancet 2002; 360: 1831-1837.
24. Cines D B, Blanchette V S. Immune thrombocytopenic purpura. N Engl J Med 2002; 346: 995-1008.
25. Dalakas M C. Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology 2002; 59: S13-21.
26. Danieli M G, Malcangi G, Palmieri C, et al. Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis. Ann Rheum Dis 2002; 61: 37-41.
27. Winston D J, Antin J H, Wolff S N, et al. A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation. Bone Marrow Transplant 2001; 28: 187-196.
28. Alejandria M M, Lansang M A, Dans L F, Mantaring J B. Intravenous immunoglobulin for treating sepsis and septic shock. Cochrane Database Syst Rev 2002; CD001090.
29. Ott V L, Fong D C, Cambier J C. Fc gamma RIIB as a potential molecular target for intravenous gamma globulin therapy. J Allergy Clin Immunol. 2001; 108: S95-S98.
30. Kazatchkine M D, Rossi F, Sultan Y, Nydegger U. Anti-idiotypes against autoantibodies to procoagulant factor VIII (VIII:C) in intrave-nous immunoglobulins. Int Rev Immunol 1989; 5: 157-163.
31. Basta M, Kirshbom P, Frank M M, Fries L E. Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model. J Clin Invest 1989; 84: 1974-1981.
32. Rieben R, Roos A, Muizert Y, Tinguely C, Gerritsen A F, Daha M R. Immunoglobulin M-enriched human intravenous immunoglobulin prevents complement activation in vitro and in vivo in a rat model of acute inflammation. Blood 1999; 93: 942-951.